Zenas BioPharma updates pipeline timelines; obexelimab Phase 3 IgG4-RD data due year-end 2025

Zenas BioPharma, Inc.

Phase 3 INDIGO trial (IgG4-RD) topline results expected year-end 2025; over 190 patients enrolled.
Phase 2 MoonStone (RMS) primary endpoint (12-week new T1 Gd+ lesions) data expected early Q4 2025.
Phase 2 SunStone (SLE) primary endpoint (24-week BICLA) data expected mid-2026.
Q1 2025 cash of ~$314M; management expects cash runway into Q4 2026.
Prior Phase 2 IgG4-RD showed 93% ongoing response; SLE optimized exposure effect size 35% vs placebo.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.